Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 9, 2019
Daily News
December 9, 2019
- Chuikyo Pushes Up-to-5-Band Plan to Address Unreasonable Generic Price Rises, Prods Industry Reorganization
December 9, 2019
- US, European Trade Groups Oppose Tighter Re-Pricing Rules
December 9, 2019
- MSD, Taiho to Wind Up Keytruda Copromotion at Year-End
December 9, 2019
- All-Case PMS Requirement Lifted for Lenvima’s Thyroid Cancer Use
December 9, 2019
- Japan Ethical Drug Sales Up 1.7% in October: Crecon
December 9, 2019
- 8,000 Die from 2 Drug Resistant Bacteria Annually in Japan: Survey
December 9, 2019
- Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
December 9, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…